Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herb takes on modern kidney damage

NCT ID NCT07153731

Disease control Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests Shenkangling, a traditional Chinese herbal tonic, in 100 adults who experience kidney injury during surgery. The goal is to see if it helps kidneys recover and is safe. Participants take the herb twice daily, and researchers measure urine and blood markers of kidney function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Shenkangling (Chinese herbal tonic)
What this could lead to
If it works, this could provide a new treatment option to help kidneys recover after surgery-related injury.
What could go wrong
This is an early-phase trial with only 100 participants, so results may not apply to everyone. Herbal remedies can have side effects or interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Fulfillment of western medical diagnostic criteria requiring renal ischemia-reperfusion surgical operation and renal artery clamping time ≤ 30 min 2. Meets the criteria for Chinese medicine identification 3. 18 ≤ age ≤ 65 4. Voluntary participation with signed informed consent Exclusion Criteria: 1. Patients with stage 4 or 5 renal insufficiency or patients with acute renal failure 2. Those with secondary factors such as systemic lupus erythematosus, drug-induced renal damage, etc. confirmed by examination 3. Does not meet the diagnosis of renal ischemia-reperfusion injury 4. Cases not within the scope of action of the drug 5. Those who have been taking other related therapeutic drugs for a long period of time, e.g., taking Chinese medicines such as Jingui Shenqi Pills by mouth for a long period of time, or those who are unable to stop taking the medicines immediately. 6. Advanced deformity, disability, loss of labor force 7. Combined heart, brain, liver, hematopoietic system, endocrine system and other serious primary diseases and psychiatric patients 8. Pregnant or lactating women 9. Critically ill patients 10. Other circumstances deemed inappropriate for inclusion in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal ischemia-reperfusion injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemia reperfusion injury urinary system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urologic injuries Urology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    Yiwu, Zhejiang, 322000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.